J Menopausal Med.  2016 Dec;22(3):127-128. 10.6118/jmm.2016.22.3.127.

Nanomedicine Approaches for Treatment of Menopausal Symptoms

• Abdi F
• Ramezani Tehrani F
• Mobedi H
• Dolatian M
• Mosaffa N

• KMID: 2378230
• DOI: http://doi.org/10.6118/jmm.2016.22.3.127

Abstract

No abstract available.

MeSH Terms

Nanomedicine*

Reference

1. Abdi F, Mobedi H, Mosaffa N, Dolatian M, Ramezani Tehrani F. Effects of hormone replacement therapy on immunological factors in the postmenopausal period. Climacteric. 2016; 19:234–239.

2. Ahmed K, Jahan P, Nadia I, Ahmed F, Abdullah Al E. Assessment of menopausal symptoms among early and late menopausal midlife bangladeshi women and their impact on the quality of life. J Menopausal Med. 2016; 22:39–46.

3. Abdi F, Kazemi F, Ramezani Tehrani F, Roozbeh N. Protocol for systematic review and meta-analysis: hop (Humulus lupulus L.) for menopausal vasomotor symptoms. BMJ Open. 2016; 6:e010734.

4. Lim H, Kim TH, Lee HH. A study on perception and usage status on health functional foods in women according to menopause status. J Menopausal Med. 2016; 22:20–30.

5. Rees M, Moghimi SM. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Nanomedicine. 2012; 8:Suppl 1. S1–S4.

6. Botelho MA, Queiroz DB, Barros G, Guerreiro S, Fechine P, Umbelino S, et al. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics (Sao Paulo). 2014; 69:75–82.

7. Abdi F. Assessment of nanostructured transdermal phytoestrogen therapy for relieving menopausal symptoms [dissertation]. Tehran, IR: Shahid Beheshti University of Medical Sciences;2016.

8. de Vargas BA, Bidone J, Oliveira LK, Koester LS, Bassani VL, Teixeira HF. Development of topical hydrogels containing genistein-loaded nanoemulsions. J Biomed Nanotechnol. 2012; 8:330–336.

9. Valenzuela P, Simon JA. Nanoparticle delivery for transdermal HRT. Maturitas. 2012; 73:74–80.

10. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006; 13:222–231.